Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 6/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25431172 | 0.78 | GSK3A (0.42) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL18125390 | 0.76 | GSK3A (0.38) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL2379179 | 0.75 | LPL (0.40) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL30082544 | 0.74 | CDK8 (0.43) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL10565 | 0.74 | CDK8 (0.43) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL1585585 | 0.73 | GSK3A (0.45) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL1502630 | 0.73 | GSK3A (0.47) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL20658679 | 0.73 | EGFR (0.34) | LPLLIPGEGFR | |
| SCHEMBL29380963 | 0.73 | GSK3A (0.43) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL2966812 | 0.73 | GSK3A (0.43) | GSK3AGSK3BPDGFRBKDRALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286435-B2 | Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof | BIONNA (BEIJING) MEDICAL TECHNOLOGY CO., LTD. (CN) | 2025-04-29 | — | — | US | disclosed |
| US-20240116948-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-04-11 | — | — | US | disclosed |
| EP-3919479-B1 | COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF | BIONNA BEIJING MEDICAL TECH CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| EP-4267584-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136221-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-30 | — | — | WO | disclosed |
| US-20210380592-A1 | COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF | BIONNA (BEIJING) MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-09 | — | — | US | disclosed |
| EP-3919479-A1 | COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Bionna (Beijing) Medical Technology Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116948-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, TGFBR2 | GSK3A 208/4885GSK3B 123/4885PDGFRB 14/4885 |
| US-12286435-B2 | Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof | BRD4, BRD7, BICRA | GSK3A 1958/4885GSK3B 1387/4885PDGFRB 3425/4885 |
| US-20210380592-A1 | COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF | BRD4, BRD7, BICRA | GSK3A 1958/4885GSK3B 1387/4885PDGFRB 3425/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | GSK3A 630/4885GSK3B 636/4885PDGFRB 2511/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GSK3A 630/4885GSK3B 636/4885PDGFRB 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.